Alkermes plc Ordinary Shares (ALKS)
NASDAQ: ALKS · Pharmaceutical Preparations · Dublin 4, L2
Our rating: Neutral
Call changed from Cautious to Neutral at $45.89, moderate conviction, November 4, 2026.
Breaks if: The Neutral call turns Cautious if the full-year revenue run rate falls more than 10% YoY over the next twelve months, or if annual free cash flow drops below $300M in the next reported annual period — either would signal structural franchise deterioration that the current FCF-based valuation does not price in. It turns Positive if revenue returns to growth of at least 3% YoY across two consecutive quarterly filings, confirming the recent decline was transitory rather than the leading edge of a steeper trend.
Key figures
| Market value | $7.6B |
|---|---|
| Revenue, last 12 months | $1.8B |
| Net income, last 12 months | −$351000.00 |
| Free cash flow, last 12 months | $227M |
| Price to earnings | n/a |
| Free cash flow yield | 3.0% |
| Dividend yield | 0.0% |
| Operating margin | 3.7% |
| Return on equity | −0.0% |
| Beta to the S&P 500 | 0.63 |
| Volatility, annualized | 36.8% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $480M | 21.8% | $0.09 | $90M |
| June 30, 2026 | $496M | 27.0% | $0.00 | $137M |
| March 31, 2026 | $393M | 28.2% | $-0.40 | −$170M |
| December 31, 2025 | $385M | −10.6% | $0.29 | $170M |
| September 30, 2025 | $394M | 4.2% | $0.49 | $84M |
| June 30, 2025 | $391M | −2.1% | $0.52 | $137M |
| March 31, 2025 | $307M | −12.5% | $0.13 | $89M |
| December 31, 2024 | $430M | 13.9% | $0.87 | $181M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.45B: Claude 72%, Gemini 90%, Mistral 85%
- Diluted earnings per share are at least $0.29: Claude 38%, Gemini 10%, Mistral 35%
- Free cash flow for the quarter is at least $0.17B: Claude 52%, Gemini 70%, Mistral 60%
12 ledger entries and 50 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.